RadNet FY Conference Summary Company Overview - **Company**: RadNet (NasdaqGM:RDNT) - **Event**: FY Conference held on March 12, 2026 Key Points Current State and Outlook - RadNet experienced a strong performance in 2025, with revenue growth of over **14.8%** and substantial EBITDA growth, marking the best quarter in the company's history [3][6] - The company anticipates revenue growth for 2026 in the range of **17%-19%** and EBITDA growth between **18% and 22%**, indicating expected margin improvement [6] Digital Health Segment - The digital health segment is projected to grow over **50%**, driven by both organic growth and acquisitions, including the recent acquisition of Gleamer [7] - RadNet is focusing on transparency in its digital health initiatives, introducing metrics like annual recurring revenue (ARR) for better tracking [8] Acquisition of Gleamer - The acquisition of Gleamer is significant as it enhances RadNet's AI capabilities in X-ray, which is crucial since X-ray accounts for about **25%** of RadNet's procedure volume [10][12] - Gleamer has shown impressive growth, with an ARR increase of over **90%** since 2022, and RadNet expects to integrate Gleamer's technologies to improve efficiency and reduce costs [13] Revenue Synergies - RadNet estimates **$7 million** in revenue synergies from cross-selling and upselling opportunities through the integration of Gleamer [15] - The company aims to reduce reliance on RadNet as a customer for its digital health segment from **45%** in 2025 to **33%** in 2026, with a target of below **20%** by the end of 2028 [17][18] Labor Efficiency and Cost Management - Labor costs have been a significant challenge, with a **4%-5%** increase in labor costs built into the 2026 guidance [24] - Technologies like TechLive and C-mode are being implemented to improve labor efficiency, with TechLive allowing remote MRI scanning to reduce exam room closures [25][26] Industry Trends - Advanced imaging is a key growth area, currently comprising about **28.6%** of procedure volume but driving over **60%** of revenue [29] - The company is well-positioned to capture more advanced imaging as technology evolves, with expectations for continued growth in this segment [30][31] Economic Environment - RadNet has not observed any significant changes in demand or procedure volume despite broader economic concerns, indicating resilience in its operations [33] - The company benefits from favorable Medicare pricing and strong rate increases from capitated and commercial payers, recognizing the value of outpatient services compared to hospital pricing [34][35] Strategic Positioning - RadNet's strong regional presence allows it to negotiate effectively with payers, as it comprises a significant part of the outpatient imaging market in its operational areas [34][36] Conclusion - RadNet is positioned for robust growth in 2026, driven by strategic acquisitions, a focus on digital health, and advancements in imaging technology, while effectively managing labor costs and maintaining strong relationships with payers.

Financial Data and Key Metrics Changes - Total company revenue increased by 14.8% to $547.7 million, and Adjusted EBITDA increased by 16.9% to $87.7 million compared to the previous year's fourth quarter [8][17] - Digital Health revenue grew by 48.2% to $27.9 million, with Adjusted EBITDA increasing by 8.9% to $4.9 million from the same quarter last year [8][17] - Adjusted earnings per share for RadNet was flat at $0.23 per share compared to $0.04 per share in the previous year's fourth quarter [18] Business Line Data and Key Metrics Changes - Imaging center revenue growth was driven by a 14.1% aggregate and 9.6% same-center advanced imaging procedural volume growth in the fourth quarter [9][10] - Advanced imaging represented 28.6% of RadNet's procedural volume, an increase of 178 basis points from the previous year [9][10] - The Digital Health segment's revenue finished at $92.7 million, exceeding original guidance [19] Market Data and Key Metrics Changes - The company opened seven de novo facilities in 2025 to address backlogs and access points for identified patient populations [10] - 151 of RadNet's 418 centers, or 36.1%, are held within health system partnerships, which have been instrumental in increasing procedural volume [11] Company Strategy and Development Direction - The acquisition of Gleamer is expected to enhance RadNet's digital health business and expand its portfolio of AI-powered solutions [26][34] - The company aims to leverage AI to improve efficiency, productivity, and accuracy in radiology workflows, addressing labor shortages in the industry [12][26] - Future growth is anticipated through further acquisitions and partnerships, particularly in the outpatient imaging sector [11][72] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's ability to grow despite challenges in the labor market and increasing demand for imaging services [42][68] - The company expects to achieve 17%-19% imaging center revenue growth in 2026, driven by same-center performance and new acquisitions [21][22] - Management highlighted the importance of AI in enhancing the capabilities of existing staff rather than replacing them, emphasizing improved patient outcomes [44][45] Other Important Information - At year-end 2025, RadNet's cash balance was $776 million, with a net debt to Adjusted EBITDA leverage ratio of approximately 1.0 [13][20] - The company introduced a new metric, Annual Recurring Revenue (ARR), for the Digital Health segment, which was $75.4 million at the end of 2025 and is expected to approach $140 million by the end of 2026 [24][55] Q&A Session Summary Question: How does RadNet view AI's impact on radiology? - Management believes AI will enhance productivity and accuracy rather than disrupt the workforce, addressing critical needs in radiology [42][44] Question: Can you provide context on the ARR growth? - ARR is expected to grow significantly due to contributions from Gleamer and other acquisitions, with a focus on recurring revenue from contracts [55][56] Question: What efficiency gains are anticipated from the Gleamer acquisition? - The integration of Gleamer's AI capabilities is expected to improve operational efficiency, particularly in routine imaging areas [60][66] Question: Are there more opportunities for joint ventures with hospital systems? - There has been a notable increase in inquiries from hospital systems seeking partnerships, driven by staffing shortages [68][72] Question: What is the expected impact of weather conditions on EBITDA guidance? - Management anticipates labor cost increases and potential impacts from winter weather conditions to be reflected in the EBITDA guidance for 2026 [90][91]

Financial Data and Key Metrics Changes - Total company revenue increased by 14.8% to $547.7 million, while Adjusted EBITDA rose by 16.9% to $87.7 million compared to the previous year's fourth quarter [8][18] - Digital Health segment revenue grew by 48.2% to $27.9 million, with Adjusted EBITDA increasing by 8.9% to $4.9 million [8][18] - Adjusted earnings per share for RadNet was flat at $0.23 per share compared to $0.04 per share in the last year's fourth quarter [19] Business Line Data and Key Metrics Changes - Imaging center revenue was driven by a 14.1% aggregate and 9.6% same-center advanced imaging procedural volume growth [9] - Advanced imaging represented 28.6% of RadNet's procedural volume, an increase of 178 basis points from the previous year [9] - The Digital Health segment's revenue for the full year reached $92.7 million, exceeding original guidance [20] Market Data and Key Metrics Changes - The company opened seven de novo facilities in 2025 to address backlogs and access points for identified patient populations [10] - 151 of RadNet's 418 centers, or 36.1%, are held within health system partnerships, which have been instrumental in increasing procedural volume [11] Company Strategy and Development Direction - The acquisition of Gleamer is expected to enhance RadNet's Digital Health capabilities and position it as the largest provider of radiology clinical AI solutions worldwide [27][36] - The company aims to leverage AI to improve efficiency, productivity, and accuracy in imaging workflows, addressing labor shortages in the industry [26][29] - Future growth is anticipated to come from expanding joint ventures and acquisitions, particularly in new markets [10][76] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in meeting or exceeding 2025 guidance levels due to strong performance in the fourth quarter [19] - The company anticipates 17%-19% imaging center revenue growth for 2026, driven by same-center performance and new acquisitions [22] - Management highlighted the importance of AI in enhancing productivity and addressing workforce challenges in radiology [45][47] Other Important Information - At year-end 2025, RadNet's cash balance was $776 million, with a net debt to Adjusted EBITDA leverage ratio of approximately 1.0x [13] - The company introduced a new metric, Annual Recurring Revenue (ARR), for the Digital Health segment, which was $75.4 million at the end of 2025 [24] Q&A Session Summary Question: How does RadNet view AI's impact on radiology? - Management believes AI will enhance productivity and accuracy rather than disrupt the workforce, addressing critical needs in radiology [44][45] Question: Can you provide context on the ARR growth? - ARR is expected to grow significantly due to contributions from Gleamer and other acquisitions, with a target of approximately $140 million by the end of 2026 [56][87] Question: What efficiency gains are expected from the Gleamer acquisition? - The integration of Gleamer's AI capabilities is anticipated to improve operational efficiency, particularly in routine imaging areas like X-ray [70][72] Question: Are there more opportunities for joint ventures with hospital systems? - There has been a notable increase in inquiries from hospital systems seeking partnerships, driven by staffing shortages [71][76] Question: What is the expected impact of weather conditions on EBITDA guidance? - Management indicated that labor increases and adverse weather conditions are embedded in the EBITDA guidance for 2026 [93][94]

Financial Data and Key Metrics Changes - Total company revenue increased by 14.8% to $547.7 million, while Adjusted EBITDA rose by 16.9% to $87.7 million compared to the same quarter last year [6][17]. - Digital Health revenue surged by 48.2% to $27.9 million, with Adjusted EBITDA increasing by 8.9% to $4.9 million from the previous year's fourth quarter [6][17]. - Adjusted earnings per share for RadNet remained flat at $0.23 per share compared to $0.04 per share in the last year's fourth quarter [18]. Business Line Data and Key Metrics Changes - Imaging center revenue growth was driven by a 14.1% aggregate and 9.6% same-center advanced imaging procedural volume growth in the fourth quarter [6][7]. - Advanced imaging represented 28.6% of RadNet's procedural volume, an increase of 178 basis points from the same quarter last year [8][9]. Market Data and Key Metrics Changes - The demand for diagnostic imaging continues to rise, benefiting from the shift of procedural volumes from hospitals to ambulatory freestanding centers [6][10]. - RadNet's health system partnerships have increased procedural volume through physician relationships, with 36.1% of RadNet's centers held within health system partnerships [10]. Company Strategy and Development Direction - The company plans to continue expanding its digital health portfolio, focusing on AI-powered solutions to enhance workflow and clinical capabilities in radiology [11][12]. - The acquisition of Gleamer is expected to strengthen RadNet's position in the radiology AI market, enhancing operational efficiency and expanding its global footprint [26][34]. - The company anticipates significant growth in both imaging center revenue and digital health revenue, with guidance for 2026 indicating 17%-19% growth in imaging center revenue and 45%-55% growth in digital health revenue [21][22]. Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's ability to grow despite challenges in the labor market and increasing operational demands [42][45]. - The integration of AI solutions is seen as a critical need to address workforce shortages and improve productivity and accuracy in radiology [42][44]. - The company expects to achieve a strong cash and liquidity position, with a cash balance of $776 million and a net debt to Adjusted EBITDA leverage ratio of approximately 1.0 at year-end 2025 [12][20]. Other Important Information - The company opened seven new facilities in 2025 and plans to continue expanding through acquisitions and joint ventures [9][10]. - The introduction of a new metric, Annual Recurring Revenue (ARR), aims to provide better transparency into the growth of the Digital Health division, with an expected ARR of $140 million by the end of 2026 [22][23]. Q&A Session Summary Question: How does RadNet view the impact of AI on radiology? - Management believes AI will enhance productivity and accuracy rather than disrupt the workforce, addressing critical needs in radiology due to labor shortages [42][44]. Question: Can you provide context on the growth of ARR and its contributors? - The ARR is expected to grow significantly due to contributions from Gleamer and the annualization of the iCAD acquisition, alongside other product and service growth [55][56]. Question: What efficiencies are expected from the Gleamer acquisition? - The integration of Gleamer's AI capabilities is anticipated to improve operational efficiency, particularly in routine imaging areas like X-ray, allowing radiologists to focus on more complex cases [60][67]. Question: Are there increasing opportunities for joint ventures with hospital systems? - There has been a notable increase in inquiries from hospital systems seeking partnerships, driven by staffing shortages and the need for comprehensive radiology solutions [70][72]. Question: What is the expected impact of weather conditions on EBITDA guidance? - Management indicated that labor increases and adverse weather conditions are embedded in the EBITDA guidance for 2026, with anticipated labor cost increases of over $30 million [91][92].

RadNet Investor Day 2025 Summary Company Overview - **Company**: RadNet - **Event**: Investor Day 2025 - **Location**: Nasdaq Marketplace, New York City Key Industry Insights - **Healthcare Transition**: The healthcare industry is shifting from hospital-centric models to ambulatory settings, driven by patient preferences for lower-cost and more efficient care options post-COVID [11][12] - **Technology Integration**: RadNet is focusing on integrating technology, particularly AI, to enhance diagnostic accuracy and efficiency, moving from reactive detection to proactive prevention [13][14] Financial Performance - **Record Quarter**: RadNet reported a record third quarter with a revenue growth of 13.4% year-over-year and EBITDA growth of 15.2% [20][21] - **Digital Health Growth**: The digital health division experienced significant growth of 51.6% compared to the previous year [20] - **Strong Balance Sheet**: The company ended the quarter with over $800 million in cash and low leverage, indicating strong financial health [22] Operational Highlights - **Procedure Volume Growth**: MRI procedures grew by 14.8% and CT procedures by 9.4% year-over-year, with PET/CT showing over 21% growth [21][22] - **Capacity Expansion**: RadNet is actively opening new DeNovo centers and has plans for 11 additional projects next year [23][24] - **Acquisition Strategy**: The company is positioned to consolidate within the industry, leveraging scale to become a low-cost provider [24] Technological Innovations - **AI in Imaging**: RadNet is utilizing AI tools to improve workflow efficiency and patient outcomes, particularly in neuroimaging and breast cancer detection [30][39] - **Lung Cancer Screening**: The company is involved in lung cancer screening initiatives in the UK, demonstrating the effectiveness of AI in improving diagnostic accuracy and efficiency [40][48] Clinical Advancements - **Neuroimaging**: AI innovations are enhancing early disease detection and workflow efficiency in neuroimaging, with significant increases in MRI brain volumes [30][34] - **Breast Cancer Detection**: RadNet is implementing advanced imaging techniques and AI to improve early detection of breast cancer, addressing the rising incidence among younger women [54][65] - **Prostate Cancer Screening**: The company is promoting combined PSA and MRI screening to reduce mortality rates in prostate cancer [66][68] Market Opportunities - **Population Health Focus**: RadNet aims to lead in population health by diagnosing diseases earlier, thus expanding its total addressable market [28][39] - **Lung Cancer Screening Market**: The UK lung cancer screening program is expected to grow significantly, with RadNet positioned to capture a large share of this market [49][52] Conclusion - RadNet is strategically positioned to leverage technological advancements and operational efficiencies to drive growth in the evolving healthcare landscape, focusing on early disease detection and improved patient outcomes while maintaining strong financial health and expanding market presence.

Financial Data and Key Metrics Changes - Total company revenue increased by 13.4% compared to last year's third quarter, reaching a quarterly record [4][18] - Adjusted EBITDA increased by 15.2%, resulting in a 26 basis point improvement in adjusted EBITDA margins [4][21] - Cash balance as of September 30, 2025, was $804.7 million, with a net debt to adjusted EBITDA ratio of approximately 1.0 [14][22] Business Line Data and Key Metrics Changes - Advanced imaging procedures increased by 13.0% on an aggregate basis and 9.9% on a same-center basis compared to last year's third quarter [6][18] - MRI volume increased by 14.8%, CT volume by 9.4%, and PET/CT volume by 21.1% from last year's third quarter [18] - Digital health revenue increased by 51.6% from last year's third quarter, with AI revenue within digital health increasing by 112% [19][20] Market Data and Key Metrics Changes - 28.2% of procedures were from advanced imaging compared to 26.7% in the third quarter of last year [7] - The blended adoption rate for the EBCD DeepHealth AI-powered breast cancer screening program is above 45% nationally [9] Company Strategy and Development Direction - The company is focusing on expanding its digital health segment and integrating AI technologies to enhance operational efficiency and patient outcomes [10][80] - There is an ongoing initiative to pursue acquisitions that align with the company's strategic objectives in both imaging services and digital health [14][82] - The company plans to enhance its EBCD program to improve risk prediction models and early cancer detection capabilities [44] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the future, highlighting the positive trends in reimbursement rates and the shift towards more cost-effective imaging solutions [8][26] - The company anticipates a $4-$5 million uplift in Medicare revenue for 2026, breaking a trend of annual cuts [25][26] - Management acknowledged challenges in the labor market but noted stabilization and efforts to improve hiring and retention of radiology technologists [55][59] Other Important Information - The company completed the acquisition of iCAD, enhancing its capabilities in AI-powered breast health solutions [10] - The integration of CMODE's thyroid ultrasound technology has been completed across more than 240 RadNet centers, improving diagnostic accuracy [11] Q&A Session Summary Question: Update on TechLive rollout and dynamic scheduling - The TechLive rollout is expected to be substantially complete by the end of the year, significantly reducing exam room closures and increasing capacity [33][34] - Dynamic scheduling utilizes AI to predict patient no-shows, allowing for overbooking and better utilization of exam slots [36] Question: Progress on EBCD coverage and capitated contracts - Discussions with commercial payers regarding EBCD coverage are ongoing, with positive feedback expected to lead to adoption [40] - Capitated contracts are seeing increased rates, with some larger groups beginning to offer EBCD as a covered benefit [42] Question: Outlook for joint ventures and partnerships - The company is receiving more inquiries from health systems regarding radiology strategies, indicating robust interest in partnerships [50] Question: Exposure to Medicaid programs and labor costs - Medicaid fee-for-service business constitutes about 2.5% of total business, with minimal impact expected from changes in Medicaid programs [52] - Labor costs remain a challenge, but stabilization efforts are underway, including training programs and partnerships with tech schools [55] Question: Future of DeepHealth and sales personnel - The company recognizes the need for more sales personnel to effectively market DeepHealth solutions, leveraging cross-selling opportunities [90] Question: EBITDA margins and cost management - Margins improved, but the company is focused on further enhancements through digital health initiatives and AI integration [96]

Financial Data and Key Metrics Changes - Total company revenue increased by 13.4% compared to last year's third quarter, reaching a quarterly record [4][18] - Adjusted EBITDA increased by 15.2% year-over-year, resulting in a 26 basis point improvement in adjusted EBITDA margins [4][21] - Cash balance as of September 30, 2025, was $804.7 million, with a net debt to adjusted EBITDA ratio of approximately 1.0 [14][22] Business Line Data and Key Metrics Changes - Advanced Imaging revenue increased by 13.0% on an aggregate basis and 9.9% on a same-center basis compared to last year's third quarter [6][18] - MRI volume increased by 14.8%, CT volume by 9.4%, and PET/CT volume by 21.1% year-over-year [18] - Digital Health revenue increased by 51.6% from last year's third quarter, driven by contributions from iCAD [19] Market Data and Key Metrics Changes - The blended adoption rate for the EBCD DeepHealth AI-powered breast cancer screening program is above 45% nationally [9] - Medicare reimbursement is expected to increase by approximately $4 million to $5 million in 2026, breaking a trend of annual cuts [25][26] Company Strategy and Development Direction - The company plans to continue expanding its Digital Health segment and has successfully integrated iCAD's operations, achieving cost synergies ahead of schedule [10][23] - There is a focus on enhancing operational efficiency through AI and digital solutions, which are expected to improve margins and capacity [56][60] - The company is evaluating an attractive pipeline of acquisition opportunities in both core imaging services and digital health [14][82] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's ability to grow through patient referrals and contracts with radiology practices, despite challenges in the labor market [4][55] - The company anticipates that the labor market challenges may be at an inflection point, with potential stabilization in staffing issues [58][60] - Management highlighted the importance of AI in transforming healthcare delivery and improving patient outcomes [80] Other Important Information - The company will host its inaugural Investor Day, showcasing its digital health solutions and future growth strategies [27][30] - The implementation of See-Mode's thyroid ultrasound technology has shown a 30% reduction in scan time, enhancing operational efficiency [11] Q&A Session Summary Question: Update on TechLive rollout and dynamic scheduling - The TechLive rollout is expected to be substantially complete by the end of the year, significantly reducing exam room closures and increasing MRI volume [34][35] - Dynamic scheduling utilizes AI to predict patient no-shows, allowing for overbooking and better utilization of exam slots [36] Question: Progress on EBCD coverage and capitated contracts - Discussions with commercial payers regarding EBCD coverage are ongoing, with positive momentum expected [40] - Capitated payers are recognizing the value of early detection and are increasing rates for the EBCD program [42] Question: Outlook for joint ventures and partnerships - The company is receiving more inquiries from health systems regarding radiology strategies, indicating robust interest in partnerships [50][51] Question: Exposure to Medicaid programs and labor costs - Medicaid fee-for-service business constitutes about 2.5% of total revenue, with minimal impact expected from changes in Medicaid programs [52] - Labor costs remain a challenge, but the company is implementing various strategies to stabilize staffing [55] Question: Future of DeepHealth and sales personnel - The company recognizes the need for more sales personnel to effectively market DeepHealth solutions, leveraging cross-selling opportunities [90] Question: EBITDA margins and cost side considerations - The company is focused on margin improvement, with expectations that digital health initiatives will drive future margin expansion [96]

Financial Data and Key Metrics Changes - Total company revenue increased by 13.4% compared to last year's third quarter, reaching a quarterly record [4][17] - Adjusted EBITDA increased by 15.2%, resulting in a 26 basis point improvement in adjusted EBITDA margins [4][19] - Cash balance as of September 30, 2025, was $804.7 million, with a net debt to adjusted EBITDA ratio of approximately 1.0 [13][19] Business Line Data and Key Metrics Changes - Advanced imaging procedures accounted for 28.2% of total procedures, up from 26.7% in the same quarter last year [6] - Aggregate MRI volume increased by 14.8%, CT volume by 9.4%, and PET/CT volume by 21.1% compared to last year's third quarter [17] - Digital health revenue increased by 51.6% year-over-year, with AI revenue within digital health rising by 112% [18] Market Data and Key Metrics Changes - Same-center procedural volume showed robust growth, particularly in advanced imaging, with same-center advanced imaging increasing by 9.9% [5] - The company experienced a blended adoption rate of over 45% for its AI-powered breast cancer screening program [9] Company Strategy and Development Direction - The company plans to continue expanding its digital health segment and has successfully integrated iCAD's operations, achieving cost synergies ahead of schedule [10][21] - There is a focus on enhancing operational efficiency through AI and digital health solutions, which are expected to drive future growth [48][56] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the future, noting that the company will benefit from an anticipated $4-$5 million Medicare revenue uplift in 2026, breaking a trend of annual cuts [23][24] - The company is actively pursuing acquisition opportunities to further its strategic objectives in both core imaging services and digital health [14][19] Other Important Information - The company has opened five new facilities in 2025, with plans for more in the fourth quarter [17] - The integration of CMODE's thyroid ultrasound technology has improved diagnostic accuracy and enhanced clinical workflows [10] Q&A Session Summary Question: Update on TechLive rollout and dynamic scheduling - Management indicated that the TechLive rollout should be substantially complete by the end of the year, significantly reducing exam room closures and increasing MRI volume [29][30] Question: Progress on EBCD coverage and capitated contracts - Management reported positive discussions with commercial payers regarding EBCD coverage and noted that capitated contracts are beginning to offer the EBCD program as a benefit [33][36] Question: Outlook for joint ventures and partnerships - Management stated that there is robust interest from health systems in RadNet's radiology strategy, with potential partnerships expected to be announced soon [40] Question: Labor market challenges and hiring strategies - Management acknowledged ongoing challenges in hiring radiology technologists but noted stabilization and efforts to improve recruitment and retention [45][47] Question: Future of virtual radiology capabilities - Management confirmed that developing virtual radiology capabilities is an inevitability, aimed at assisting radiologists rather than replacing them [50] Question: Digital health revenue expectations for Q4 - Management clarified that digital health revenue is expected to remain strong, with an increase in guidance reflecting the contribution from iCAD [65]

Financial Data and Key Metrics Changes - Total company revenue increased by 8.4% to a quarterly record of $498,200,000 compared to the same quarter last year [8][24] - Adjusted EBITDA rose by 12.3% to a record $81,200,000, up from $72,300,000 in the previous year [13][24] - Adjusted EBITDA margin improved to 16.3%, compared to 15.7% in the same quarter last year, reflecting a margin expansion of almost 60 basis points [13][24] Business Line Data and Key Metrics Changes - Digital health segment revenue increased by 30.9% to a quarterly record of $20,700,000 [8][24] - Advanced imaging procedures grew by 9% in aggregate and 6.6% on a same-center basis compared to last year's second quarter [22] - PETCT procedures saw a significant increase of 22.4% on an aggregate basis and 16.2% on a same-center basis [11][22] Market Data and Key Metrics Changes - The company reported a cash balance of $833,000,000 and a net debt to adjusted EBITDA ratio of 0.96 as of June 30, 2025 [18][26] - Days sales outstanding (DSOs) improved to 32.4 days, slightly lower than the previous year [26] Company Strategy and Development Direction - The company is focusing on expanding advanced imaging procedures and enhancing operational efficiency through technology such as TechLive and C Mode [12][35] - There is a strong emphasis on integrating AI solutions to improve diagnostic accuracy and operational workflows [33][35] - The company plans to open nine additional facilities by the end of the year and has 11 more in development for 2026, indicating a commitment to expanding capacity [23][47] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the recovery from disruptions caused by wildfires and severe weather, highlighting a return to growth [8][22] - The anticipated increase in Medicare reimbursement rates is expected to provide a revenue uplift of approximately $4 to $5 million in 2026 [30][31] - The company is confident in its ability to invest its cash balance in opportunities that align with strategic objectives [18][27] Other Important Information - The acquisition of iCAD and C Mode Technology is expected to enhance the company's capabilities in AI-powered diagnostic solutions [15][16] - The company is actively evaluating a pipeline of acquisition opportunities in both core imaging services and digital health [18][67] Q&A Session Summary Question: Can you discuss the anticipated capacity increase from new technologies and facilities? - Management highlighted a 40% reduction in MRI room closures due to TechLive, which significantly increases capacity [40][41] - The company expects to add 22 additional centers, representing a 5% increase in capacity [47][48] Question: What is the initial feedback from the iCAD customer base regarding cross-selling opportunities? - Management indicated it is early in the integration process but is pleased with the quality of the sales and marketing teams [49] Question: How does the company view the impact of EBCD reimbursement announcements on payer conversations? - Management noted that the endorsement from a capitated group for EBCD is expected to influence other payers positively [51] Question: What are the anticipated margins from the implementation of new technologies? - Management expects substantial flow-through margins as more scans are performed in existing facilities without significant additional costs [65] Question: How is the company planning to allocate capital for M&A and de novo facilities? - The company plans to focus on traditional imaging center acquisitions while also evaluating digital health opportunities [67]

Financial Data and Key Metrics Changes - Total company revenue for Q2 2025 reached a record $498.2 million, an increase of 8.4% compared to the same quarter last year [8][24] - Adjusted EBITDA also set a quarterly record at $81.2 million, up 12.3% from $72.3 million in Q2 2024, with an adjusted EBITDA margin of 16.3%, improving from 15.7% year-over-year [14][24] Business Line Data and Key Metrics Changes - The digital health segment reported revenue of $20.7 million, a significant increase of 30.9% from the previous year [24] - Advanced imaging procedures grew by 9% in aggregate and 6.6% on a same-center basis compared to Q2 2024, with PETCT being the fastest-growing modality, increasing 22.4% in aggregate [22][24] Market Data and Key Metrics Changes - The company experienced a rebound in business following disruptions from California wildfires and severe winter weather, leading to a return to anticipated growth levels [8][22] - The shift of procedural volumes from hospitals to more cost-effective ambulatory centers continues to drive growth in the imaging sector [9] Company Strategy and Development Direction - The company is focusing on expanding advanced imaging capacity and improving operational efficiency through technology investments, including the implementation of TechLive and acquisitions like iCAD and C Mode [13][16][32] - The strategy includes enhancing patient diagnosis and outcomes through AI-powered solutions and expanding the digital health segment [15][16][32] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about future growth, citing improvements in reimbursement rates and the ongoing demand for advanced imaging procedures [9][10][14] - The company anticipates a modest increase in Medicare reimbursement rates for 2026, which could result in an additional $4 to $5 million in revenue [29] Other Important Information - As of June 30, 2025, the company had a cash balance of $833 million and a net debt to adjusted EBITDA ratio of 0.96, indicating strong financial liquidity [18][26] - The company plans to open nine new facilities by the end of 2025 and has additional projects in the pipeline for 2026 [22][44] Q&A Session Summary Question: Can you discuss the anticipated capacity increase from new technologies and facilities? - Management highlighted a 40% reduction in MRI room closures due to TechLive, which has significantly increased capacity in high-demand areas like New York [38][39] Question: What initial feedback has been received from the iCAD customer base? - Management noted that it is early in the integration process but expressed satisfaction with the quality of the sales and marketing teams and the potential for cross-selling opportunities [47] Question: How does the company view the impact of EBCD reimbursement announcements? - Management indicated that the endorsement from a capitated group for EBCD could encourage other payers to recognize its value, leading to broader adoption [49][50] Question: What is the outlook for M&A and capital deployment? - The company is focusing on traditional imaging center acquisitions and evaluating digital health opportunities, with plans to deploy capital in the second half of the year [66][68] Question: What are the expected margins from the deployment of new technologies? - Management anticipates substantial margin improvements from increased efficiency and capacity utilization through the implementation of AI and operational tools [64][81]